Author

Marta Isabel Calvo Moya

ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE
ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE

INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY
INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY

Marta Isabel Calvo Moya  et al.

ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE
ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE

Marta Isabel Calvo Moya  et al.

LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROM GETECCU
LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROM GETECCU

Marta Isabel Calvo Moya  et al.

Item 1 - 4 / 4
1